Li Jiliang, Sato Masahiko, Jerome Chris, Turner Charles H, Fan Zaifeng, Burr David B
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
J Bone Miner Metab. 2005;23 Suppl:48-54. doi: 10.1007/BF03026323.
Long-term suppression of bone turnover with alendronate has previously been shown to increase the degree of mineralization and accumulation of microdamage in animal bones. In an effort to ascertain if other suppressors of bone resorption can also affect mineralization and microdamage accumulation, we evaluated bones from cynomolgus macaques treated with raloxifene or conjugated equine estrogens (CEE). Cynomolgus monkeys (Macaca fascicularis) were randomized, ovariectomized (except for Sham controls), and orally treated each day for 2 years with vehicle (Sham and Ovx controls), 1 mg/kg raloxifene (R1), 5 mg/kg raloxifene (R5), or 0.04 mg/kg CEE. The functional quality of the mineralized matrix was analyzed postnecropsy by biomechanical testing, histomorphometry, biochemistry, and nanoindentation. Failure testing of the whole vertebra showed no significant differences in vertebral strength among groups. Similarly, failure testing of a beam of pure bone that was machined from the femoral diaphysis also showed no differences in material strength (ultimate stress) between groups. Histomorphometry of the L2 centrum showed that Ovx tended to increase activation frequency relative to Sham controls. Estrogen (CEE) treatment for 2 years at about four times the clinical exposure tended to reduce activation frequency (Ac.f) by 41% compared to Ovx. Treatment with raloxifene at either approximately the clinical dose or five times higher nonsignificantly lowered Ac.f by 34% and 23%, respectively, relative to Ovx. Raloxifene had similar effects on serum osteocalcin, a biochemical measure of systemic bone turnover. Analysis of microcrack surface density in the cancellous bone of L3 showed a 40% reduction for Ovx relative to Sham. CEE microcrack surface density was not different than Sham whereas the R5 crack density was significantly less than Sham and CEE. R1 microcrack surface density was not significantly different from Sham or Ovx. No significant differences in crack length were observed among the groups. Hardness, which is a measure of the state of mineralization, and elastic modulus were measured for both trabecular bone on a micron scale by nanoindentation. No significant differences between groups were observed. In summary, differences in functional bone quality of the lumbar spine were not observed between Sham, Ovx, or treated monkeys. CEE increased microcracks from Ovx to Sham levels, whereas raloxifene had no effect on microdamage accumulation. We conclude that suppressing bone turnover by 40% or less offers protection against microdamage accumulation that could result in an increased risk of vertebral fracture.
先前的研究表明,长期使用阿仑膦酸盐抑制骨转换可增加动物骨骼的矿化程度和微损伤积累。为了确定其他骨吸收抑制剂是否也会影响矿化和微损伤积累,我们评估了用雷洛昔芬或共轭马雌激素(CEE)治疗的食蟹猴的骨骼。将食蟹猴(食蟹猕猴)随机分组,进行卵巢切除术(假手术对照组除外),并每天口服给予载体(假手术和去卵巢对照组)、1mg/kg雷洛昔芬(R1)、5mg/kg雷洛昔芬(R5)或0.04mg/kg CEE,持续2年。死后通过生物力学测试、组织形态计量学、生物化学和纳米压痕分析矿化基质的功能质量。整个椎体的破坏测试显示各组之间的椎体强度无显著差异。同样,从股骨干加工而成的纯骨梁的破坏测试也显示各组之间的材料强度(极限应力)无差异。L2椎体的组织形态计量学显示,与假手术对照组相比,去卵巢组倾向于增加激活频率。以约四倍临床暴露剂量进行2年的雌激素(CEE)治疗相对于去卵巢组倾向于使激活频率(Ac.f)降低41%。以大约临床剂量或五倍高剂量的雷洛昔芬治疗相对于去卵巢组分别使Ac.f非显著降低34%和23%。雷洛昔芬对血清骨钙素也有类似影响,血清骨钙素是全身骨转换的生化指标。L3松质骨微裂纹表面密度分析显示,相对于假手术组,去卵巢组降低了40%。CEE的微裂纹表面密度与假手术组无差异,而R5的裂纹密度显著低于假手术组和CEE。R1的微裂纹表面密度与假手术组或去卵巢组无显著差异。各组之间未观察到裂纹长度的显著差异。通过纳米压痕在微米尺度上测量了小梁骨的硬度(矿化状态的指标)和弹性模量。各组之间未观察到显著差异。总之,在假手术组、去卵巢组或治疗组的猴子之间未观察到腰椎功能骨质量的差异。CEE使微裂纹从去卵巢组水平增加到假手术组水平,而雷洛昔芬对微损伤积累无影响。我们得出结论,将骨转换抑制40%或更低可预防可能导致椎体骨折风险增加的微损伤积累。